Natalizumab Re-Initiation of Dosing
Public ClinicalTrials.gov record NCT00306592. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, or C-1803 and a Dosing Suspension Safety Evaluation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives of this study are to further evaluate the safety of natalizumab (Tysabri®) monotherapy by evaluating the risk of hypersensitivity and immunogenicity following re-exposure to natalizumab, and to confirm the safety of switching to natalizumab from interferon beta (IFN-β), glatiramer acetate (GA), or other multiple sclerosis (MS) therapies.
Study identification
- NCT ID
- NCT00306592
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 404 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2006 (Type not available)
- Primary completion
- Dec 2007 (Actual)
- Completion
- Feb 2008 (Actual)
- Last update posted
- Mar 21, 2017
2006 – 2008
United States locations
- U.S. sites
- 53
- U.S. states
- 28
- U.S. cities
- 49
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35233 | — |
| Research Site | Phoenix | Arizona | 85006 | — |
| Research Site | Scottsdale | Arizona | 85259 | — |
| Research Site | Little Rock | Arkansas | 72205 | — |
| Research Site | Berkeley | California | 94705 | — |
| Research Site | Los Angeles | California | 90033 | — |
| Research Site | Redwood City | California | 94063 | — |
| Research Site | Sacramento | California | 95817 | — |
| Research Site | San Francisco | California | 94117 | — |
| Research Site | Colorado Springs | Colorado | 80919 | — |
| Research Site | New Haven | Connecticut | 06510 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Maitland | Florida | 32751 | — |
| Research Site | Miami | Florida | 33136 | — |
| Research Site | Pompano Beach | Florida | 33060 | — |
| Research Site | Atlanta | Georgia | 30327 | — |
| Research Site | Arlington | Illinois | 60007 | — |
| Research Site | Chicago | Illinois | 60612 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Northbrook | Illinois | 60062 | — |
| Research Site | Des Moines | Iowa | 50314 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | Baltimore | Maryland | 21201 | — |
| Research Site | Worcester | Massachusetts | 01655 | — |
| Research Site | East Lansing | Michigan | 48824 | — |
| Research Site | Farmington Hills | Michigan | 48334 | — |
| Research Site | Teaneck | New Jersey | 07666 | — |
| Research Site | Albuquerque | New Mexico | 87131 | — |
| Research Site | Albany | New York | 12208 | — |
| Research Site | Buffalo | New York | 14203 | — |
| Research Site | Great Neck | New York | 10019 | — |
| Research Site | New York | New York | 10003 | — |
| Research Site | New York | New York | 10319 | — |
| Research Site | Staten Island | New York | 10305 | — |
| Research Site | Syracuse | New York | 13202 | — |
| Research Site | Charlotte | North Carolina | 28207 | — |
| Research Site | Raleigh | North Carolina | 27607 | — |
| Research Site | Fargo | North Dakota | 58103 | — |
| Research Site | Cincinnati | Ohio | 45219 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Portland | Oregon | 97225 | — |
| Research Site | Allentown | Pennsylvania | 18103 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Philadelphia | Pennsylvania | 19146 | — |
| Research Site | Pittsburgh | Pennsylvania | 15212 | — |
| Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Research Site | Memphis | Tennessee | 38163 | — |
| Research Site | Nashville | Tennessee | 37215 | — |
| Research Site | Dallas | Texas | 75214 | — |
| Research Site | Round Rock | Texas | 78681 | — |
| Research Site | Burlington | Vermont | 05401 | — |
| Research Site | Charlottesville | Virginia | 22903 | — |
| Research Site | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00306592, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 21, 2017 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00306592 live on ClinicalTrials.gov.